Albuquerque, NM, United States of America

Bryce Chackerian

This inventor holds 23 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Vaccine Development. Top assignees: The University of New Mexico, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Sandia Corporation. Active years: 2004-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bryce Chackerian. Retrieved from https://idiyas.com/inventor/bryce-chackerian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 17)

% Patents Active = 91.3

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 85(Granted Patents)

Location History:

Chevy Chase, MD (US) (2004 - 2011)
Albuquerque, NM (US) (2015 - 2023)

Company Filing History:

18 out of 943

The University of New Mexico

patents

7 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Johns Hopkins University

7. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2024

Loading Chart...

Areas of Expertise:

Malaria Immunogen

VLP Technology

Cancer Targeted Delivery

PCSK9 Peptide

RSV Glycoprotein

Affinity Selection

Immunogenic HPV

Virus-Like Particles

Therapeutic Methods

Serum Triglycerides

Peptide Display

Autoantibodies

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12162916 - Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (ASC) and methods of use (2024-12-10),

2. 12161710 - Malaria immunogen and methods for using same (2024-12-10),

3. 12121574 - Malaria immunogen and methods for using same (2024-10-22),

4. 11696941 - Compositions comprising a PCSK9 peptide conjugated to a qbeta carrier and methods of using the same (2023-07-11),

5. 11633471 - Compositions and methods for reducing serum triglycerides (2023-04-25),

6. 11530242 - EGFRvIII immunogen and methods for using same (2022-12-20),

7. 10925938 - Composition comprising PCSK9 peptide conjugated to a Qbeta carrier and methods of using the same (2021-02-23),

8. 10821167 - VLP-based vaccines for targetingsecreted virulence factors (2020-11-03),

9. 10279019 - PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same (2019-05-07),

10. 9943580 - Malaria vaccine (2018-04-17),

11. 9884107 - Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods (2018-02-06),

12. 9803189 - Virus-like platform for rapid vaccine discovery (2017-10-31),

13. 9717783 - Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods (2017-08-01),

14. 9549976 - Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles (2017-01-24),

15. 9533057 - Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods (2017-01-03),

Title: Innovations and Contributions of Bryce Chackerian

Introduction

Bryce Chackerian is a distinguished inventor based in Albuquerque, NM, known for his significant contributions to the field of immunology through his extensive portfolio of patents. With a total of 23 patents to his name, Chackerian has developed several innovative solutions aimed at addressing various medical challenges.

Latest Patents

Among his latest patents are groundbreaking compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (ASC). This innovation encompasses an immunogen that combines an immunogenic carrier with an antigenic ASC peptide linked to the carrier. Notably, the immunogenic carrier can be a Qβ virus-like particle (VLP), allowing the formulation of a composition that holds potential for treating inflammatory medical conditions.

Another notable patent involves a malaria immunogen, which includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide. This has implications for both prevention and treatment of malaria, presenting a valuable tool for combating this infectious disease.

Career Highlights

Bryce Chackerian's career includes significant roles at prominent institutions, such as STC.UNM and UNM Rainforest Innovations. His work at these organizations has helped to advance research and innovation in the field of medical science, particularly in the development of immunotherapies.

Collaborations

Throughout his career, Chackerian has collaborated with esteemed colleagues, including David S. Peabody and John T. Schiller. These partnerships have fostered a collaborative environment that enhances the development and practical application of innovative immunogenic compositions and methodologies.

Conclusion

In summary, Bryce Chackerian stands out as a prolific inventor in Albuquerque, NM, contributing valuable advancements in immunology through his patents. His work not only showcases the potential for treating critical medical conditions but also reflects a commitment to collaboration in the scientific community. As the landscape of medical innovations continues to evolve, Chackerian's contributions are likely to leave a lasting impact.

Profile summary based on public USPTO records.